HUTCHMED (China) Limited (AIM:HCM)
224.00
+3.00 (1.36%)
Jan 14, 2026, 4:29 PM GMT
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $138.84M USD in the half year ending June 30, 2025, a decrease of -9.16%. This brings the company's revenue in the last twelve months to $602.20M, down -1.41% year-over-year. In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%.
Revenue (ttm)
$602.20M
Revenue Growth
-1.41%
P/S Ratio
4.32
Revenue / Employee
$332.52K
Employees
1,811
Market Cap
1.90B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
| Dec 31, 2018 | 214.11M | -27.09M | -11.23% |
| Dec 31, 2017 | 241.20M | 25.12M | 11.63% |
| Dec 31, 2016 | 216.08M | 37.88M | 21.25% |
| Dec 31, 2015 | 178.20M | 90.87M | 104.06% |
| Dec 31, 2014 | 87.33M | 41.36M | 89.97% |
| Dec 31, 2013 | 45.97M | 23.60M | 105.53% |
| Dec 31, 2012 | 22.37M | -142.66M | -86.45% |
| Dec 31, 2011 | 165.03M | 127.17M | 335.88% |
| Dec 31, 2005 | 37.86M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
HUTCHMED (China) News
- 7 days ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 7 days ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 7 days ago - HUTCHMED's ESLIM-02 Trial Of Sovleplenib In Warm Autoimmune Hemolytic Anemia Meets Key Goal - Nasdaq
- 7 days ago - HUTCHMED's Sovleplenib Reaches Phase III Goal In Warm Autoimmune Hemolytic Anemia Trial In China - Nasdaq
- 7 days ago - HCM's Sovleplenib Trial Achieves Key Milestone in Treating Autoimmune Hemolytic Anemia - GuruFocus
- 7 days ago - HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewsWire
- 9 days ago - HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer - Nasdaq
- 9 days ago - Hutchmed (HCM) Commences Phase III Trial for Pancreatic Cancer Treatment - GuruFocus